Follow-up on primary prevention trials

Current Opinion in Lipidology

Volumn 9, Issue 6, 1998, Pages 551-556

  Marais, A D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG COST; HIGH RISK PATIENT; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; RISK FACTORS;

EID: 0032406180     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199812000-00006     Document Type: Review

References (49)

1. Keys A. Seven Countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press; 1980.
2. Slack J. Risk ot ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969; ii:1380-1382.
3. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97:946-952. This is a comprehensive review of the cholesterol lowering studies, which include the recent landmark statin studies but not AFCAPS/TexCAPS. The analysis finds statins very favourable in view of their safety and powerful lipid lowering effects.
4. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621-627.
5. Committee of Principal Investigators, WHO Clofibrate trial: WHO Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: report. Br Heart J 1978; 40: 1069-1118.
6. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
7. Lipid Research Clinics Program. The Lipid Clinics Coronary Primary Prevention Trial results, I.: reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251:351-364.
8. Dorr AE, Gundersen K, Schneider JC, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chron Dis 1978; 31:5-14.
9. Shepherd J, Cobbe SM, Ford I. Isles CG, Lorimer AR, Macfarlane PW, etal., for the West of Scotland Coronary Prevention Study Group. Prevention of heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
12. Holme I. Improved targeting of primary prevention after WOSCOPS. Nutr Metab Cardiovasc Dis 1997; 7:344-351. This is a clear and thorough review of primary preventive trials demonstrating a log-linear relationship in coronary heart disease reduction in relation to cholesterol reduction. The authors also discuss improved targeting.
13. West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18:1718-1724. This analysis is of interest not only for those involved in drug trials, but also for those in clinical practice. The discussion points out some pitfalls in assessing compliance.
14. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445. The data contained in this paper will be under close scrutiny for a long period in order that decisions of great clinical practice significance can be made for both LDL cholesterol lowering and other effects of statin treatment.
15. Jeppeson J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-1036.
16. Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97:1446-1452.
17. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 97:1453-1460.
18. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. Circulation 1991: 83:357-363.
19. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettit D, McMurray J, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br Med J 1997; 315:1577-1582. A careful analysis with clear definitions of transition to various disease categories in the WOSCOPS data. It indicates that treatment for selected high individuals is not very costly.
20. Downs JR, Beere PA, Whitney E, Clearfield M, Weis, Rochen J, et al. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997; 80:287-293. The publication of the design of this study preceded that of the results. The paper describes very carefully how the study was planned, emphasizing the documentation of first unstable angina episodes in the study.
21. Downs JR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622. The results of this landmark study, which will serve as a reference for intervention in moderate dyslipoproteinaemia, are given. The discussion contains good comparisons with other studies.
22. Simon A. Coronary risk estimation and treatment of hypercholesterolemia. Circulation 1997; 96:2449-2452. A short but useful paper giving the current perspective on the rationale for treatment of hypercholesterolaemia acccording to risk. Limitations and pitfalls are indicated in cholesterol treatment, and a number of proposals are made for risk based treatment.
23. Grundy SM. Primary prevention of coronary heart disease: role of cholesterol control in the United States. J Intern Med 1997; 241:295-306. A comprehensive review covering primary prevention in various categories in high and moderate categories and emphasizing dietary changes and obesity control.
24. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847. This is a very useful, practical update by which the risk of coronary artery disease can be more accurately determined than was previously possible with the Framingham study. The age, LDL cholesterol or total cholesterol, HDL cholesterol, blood pressure, diabetes and smoking scores were derived and summed, and a risk score was created. The 10-year risk of coronary artery disease was predicted to be between 1% and > 56%.
25. Avins AL, Browner WS. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels. What a difference a decade makes. J Am Med Assoc 1998; 279:445-449. The better risk allocation by simple modifications of the NCEP II classification from this paper should translate to more sensible clinical practice. According to these calculations, older men deserve more treatment than may be recommended by current guidelines, while the trend to treat young women with high LDL concentrations should be reduced.
26. Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 1993; 269:3015-3023.
27. Gotto SM. Cholesterol management in theory and practice. Circulation 1997; 96:4424-4430. A comprehensive but short review giving a background to the pathophysiology and benefits of cholesterol lowering treatment, and highlighting the impact of statins.
28. Gotto SM. Results of recent large cholesterol-lowering trials and implications for clinical management. Am J Cardiol 1997; 79:1663-1665. A very brief article providing essential background trial information and outlining the unresolved issues in management. Optimal target LDL concentrations, absolute concentration or percentage change of LDL and secondary prevention in individuals with low LDL concentration are succinctly discussed.
29. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the task force on risk reduction. Circulation 1997; 95:2329-2331. This is a brief but comprehensive article giving a table of risk interventions to perform for patients, with recommendations and a guide to physical activity, body mass control, and drug choice.
30. Fletcher GF. How to implement physical activity in primary and secondary prevention. A statement for healthcare professionals from the task force on risk reduction, American Heart Association. Circulation 1997; 96:355-357. Practical guidelines are given for primary and secondary prevention. For primary prevention, recreational sport is emphasized. For secondary prevention, early activity involves walking while late activity a symptom-limited exercise test is advised before greater activity is encouraged in an approach that stratifies individuals according to myocardial ischaemia or arrhythmia risk.
31. Barnard RJ, DiLauro SC, Inkeles SB. Effects of intensive diet and exercise intervention in patients taking cholesterol-lowering drugs. Am J Cardiol 1997; 79:1112-1114. A brief paper describing a study involving high risk individuals in a very strict dietary regimen, supervised exercise and education. Having achieved a LDL cholesterol change of 20% by drugs, a further 19% reduction was achieved. Exposure to this in a 3-week program was better than a shorter exposure of 1 week.
32. Bramlet DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. Am J Cardiol 1997; 80:39H-44H.
33. Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk. Observations and predictions among middle-aged population in Eastern Finland. Circulation 1998; 97:1087-1094. This large scale study demonstrates that a reduction in coronary mortality by one-half was accompanied by a shift to lower cholesterol concentration in the whole population. This was achieved by health education and promotion of low saturated fat intakes. The relative risk of coronary artery disease between cholesterol concentrations of <5 and >8 mmol/l is five times. Owing to the high prevalence of coronary artery disease, a community-based approach was necessary and effective.
34. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997; 131:1-5. A brief article that examines the angiographic and clinical outcome studies to conclude that the percentage decrease in LDL cholesterol provides a better index of outcome than the absolute level of LDL on treatment. This kind of approach could simplify management to 25% reductions of LDL cholesterol for primary and 33% for secondary prevention, in moderate dyslipoproteinaemias.
35. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-1439. This is a very well-written editorial that considers the emerging data about risk reduction and LDL reduction, and concludes that there is likely a curvilinear relationship. It compares these findings with NCEP guidelines and shows that these findings are in support of most of the guidelines.
36. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80:106-107.
37. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T. Barrettconnor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96:7, 2468-2482. A very detailed document giving a good account of epidemiology, diagnosis, prognosis and management in coronary heart disease and stroke.
38. LaRosa JC. Cholesterol management in women and the elderly. J Intern Med 1997; 241:307-316. This review briefly summarizes the knowledge about women with cardiovascular disease, stressing that risk factors are similar to the exception triglyceride concentrations which appear to be a stronger risk indicator in women. The fact that women lose their gender advantage for cardiovascular disease is stressed. The authors note that hormone replacement therapy has not conclusively been shown to be beneficial for cardiovascular protection. The section on the elderly indicates that risk is still dependent on cholesterol and that there is no reason to suspect that the vascular biology is very different. The authors are cautious in recommending primary prevention but support secondary prevention.
39. Oliver MF. Should we treat hypercholesterolaemia in patients over 65? Heart 1997; 77:491-492. An editorial which succinctly discusses the different options of management in the elderly. There is support for secondary prevention but the inclination is for no drugs for primary prevention unless a case can be made for high risk.
40. Colwell JA. Pharmacological strategies to prevent macrovascular disease in NIDDM. Diabetes; 1997: 46: S131-S134.
41. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 1997; 278:313-321.
42. Blauw GJ, Lagaay M, Smelt AHM, Westendorp RGJ. Stroke, Statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28:946-950.
43. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128:89-95.
44. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28:2315-2320.
45. Gotto AM. Statin thereapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease. Arch Intern Med 1997; 157:1283-1284. An editorial that succinctly summarizes the beneficial findings of secondary and primary prevention but which is still reserved about statin prescription for stroke prevention.
46. Gotto AM. The new cholesterol education imperative and some comments on niacin. Am J Cardiol 1998; 81:492-494.
47. Lamarche B, Tehernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després J-P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation 1997; 95:69-75.
48. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37-45.
49. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-2011.